Skip to main content
. 2022 Nov 18;17:5447–5468. doi: 10.2147/IJN.S380515

Figure 2.

Figure 2

Evaluation of the therapeutic effect of ginsenoside Rg1-CNV. (A) Longa scoring experiment N=5. (B) Brain TCC staining N=5. (C) Infarct area ratio N=5. (D) Histochemistry N=3. (E) Nissl’s staining N=3. (F) Immunocytochemistry of CD31 markers N=3. (G) The number of new blood vessel N=3. * P<0.05, ** P<0.01.